GRI Bio (GRI) Retained Earnings (2020 - 2026)
GRI Bio (GRI) posted quarterly Retained Earnings of -$53.7 million for Q1 2026, down 25.49% year-over-year from -$72.1 million in Q1 2025, and down 3.86% quarter-over-quarter from -$51.7 million in Q4 2025.
GRI Bio (GRI) Retained Earnings (2020 - 2026) Analysis & Trends
GRI Bio's Retained Earnings history runs 7 years deep, the most recent figure standing at -$53.7 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 25.49% year-over-year to -$53.7 million; the TTM figure through Mar 2026 stood at -$53.7 million (down 25.49% YoY), while the FY2025 annual figure was -$51.7 million, down 30.09% from the prior year.
- Retained Earnings for Q1 2026 stood at -$53.7 million, down from -$51.7 million in the prior quarter.
- The five-year high for Retained Earnings was -$1000.0 in Q3 2022, with the low at -$53.7 million in Q1 2026.
- The 5-year median for Retained Earnings is -$33.4 million (2024), against an average of -$32.5 million.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings soared 99.98% in 2022, then slumped 2952800.0% in 2023.
- GRI Bio's Retained Earnings stood at -$18.5 million in 2022, then plunged by 70.49% to -$31.5 million in 2023, then slipped by 26.03% to -$39.7 million in 2024, then tumbled by 30.09% to -$51.7 million in 2025, then retreated by 3.86% to -$53.7 million in 2026.
- Business Quant data shows GRI's Retained Earnings at -$53.7 million in Q1 2026, -$51.7 million in Q4 2025, and -$49.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | GRI Bio | 3.07 Mn | 3.07 Mn | - | -55.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.69 Mn |
| Dec 31, 2025 | -51.70 Mn |
| Sep 30, 2025 | -49.04 Mn |
| Jun 30, 2025 | -45.68 Mn |
| Mar 31, 2025 | -42.79 Mn |
| Dec 31, 2024 | -39.74 Mn |
| Sep 30, 2024 | -37.79 Mn |
| Jun 30, 2024 | -35.67 Mn |
| Mar 31, 2024 | -33.42 Mn |
| Dec 31, 2023 | -31.53 Mn |
| Sep 30, 2023 | -29.53 Mn |
| Jun 30, 2023 | -27.39 Mn |
| Mar 31, 2023 | -31.32 Mn |
| Dec 31, 2022 | -18.50 Mn |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | -3,000.00 |
| Mar 31, 2022 | -24.54 Mn |
| Dec 31, 2021 | -2,000.00 |
| Sep 30, 2021 | -1,000.00 |
| Jun 30, 2021 | -17.55 Mn |